407 related articles for article (PubMed ID: 30652248)
1. ADGRL3 rs6551665 as a Common Vulnerability Factor Underlying Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder.
Kappel DB; Schuch JB; Rovaris DL; da Silva BS; Müller D; Breda V; Teche SP; S Riesgo R; Schüler-Faccini L; Rohde LA; Grevet EH; Bau CHD
Neuromolecular Med; 2019 Mar; 21(1):60-67. PubMed ID: 30652248
[TBL] [Abstract][Full Text] [Related]
2. An Ultraconserved Brain-Specific Enhancer Within ADGRL3 (LPHN3) Underpins Attention-Deficit/Hyperactivity Disorder Susceptibility.
Martinez AF; Abe Y; Hong S; Molyneux K; Yarnell D; Löhr H; Driever W; Acosta MT; Arcos-Burgos M; Muenke M
Biol Psychiatry; 2016 Dec; 80(12):943-954. PubMed ID: 27692237
[TBL] [Abstract][Full Text] [Related]
3. Dissociation of impulsivity and aggression in mice deficient for the ADHD risk gene Adgrl3: Evidence for dopamine transporter dysregulation.
Mortimer N; Ganster T; O'Leary A; Popp S; Freudenberg F; Reif A; Soler Artigas M; Ribasés M; Ramos-Quiroga JA; Lesch KP; Rivero O
Neuropharmacology; 2019 Sep; 156():107557. PubMed ID: 30849401
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis and systematic review of ADGRL3 (LPHN3) polymorphisms in ADHD susceptibility.
Bruxel EM; Moreira-Maia CR; Akutagava-Martins GC; Quinn TP; Klein M; Franke B; Ribasés M; Rovira P; Sánchez-Mora C; Kappel DB; Mota NR; Grevet EH; Bau CHD; Arcos-Burgos M; Rohde LA; Hutz MH
Mol Psychiatry; 2021 Jun; 26(6):2277-2285. PubMed ID: 32051549
[TBL] [Abstract][Full Text] [Related]
5. Brain structural and functional substrates of ADGRL3 (latrophilin 3) haplotype in attention-deficit/hyperactivity disorder.
Moreno-Alcázar A; Ramos-Quiroga JA; Ribases M; Sánchez-Mora C; Palomar G; Bosch R; Salavert J; Fortea L; Monté-Rubio GC; Canales-Rodríguez EJ; Milham MP; Castellanos FX; Casas M; Pomarol-Clotet E; Radua J
Sci Rep; 2021 Jan; 11(1):2373. PubMed ID: 33504901
[TBL] [Abstract][Full Text] [Related]
6. Expression of the adult ADHD-associated gene
McNeill RV; Palladino VS; Brunkhorst-Kanaan N; Grimm O; Reif A; Kittel-Schneider S
World J Biol Psychiatry; 2021 Jun; 22(5):335-349. PubMed ID: 32787626
[TBL] [Abstract][Full Text] [Related]
7. CDH13 and LPHN3 Gene Polymorphisms in Attention-Deficit/Hyperactivity Disorder: Their Relation to Clinical Characteristics.
Özaslan A; Güney E; Ergün MA; Okur İ; Yapar D
J Mol Neurosci; 2021 Feb; 71(2):394-408. PubMed ID: 32691279
[TBL] [Abstract][Full Text] [Related]
8. Genetic Variation Underpinning ADHD Risk in a Caribbean Community.
Puentes-Rozo PJ; Acosta-López JE; Cervantes-Henríquez ML; Martínez-Banfi ML; Mejia-Segura E; Sánchez-Rojas M; Anaya-Romero ME; Acosta-Hoyos A; García-Llinás GA; Mastronardi CA; Pineda DA; Castellanos FX; Arcos-Burgos M; Vélez JI
Cells; 2019 Aug; 8(8):. PubMed ID: 31426340
[TBL] [Abstract][Full Text] [Related]
9. Association of LPHN3 rs6551665 A/G polymorphism with attention deficit and hyperactivity disorder in Korean children.
Hwang IW; Lim MH; Kwon HJ; Jin HJ
Gene; 2015 Jul; 566(1):68-73. PubMed ID: 25871512
[TBL] [Abstract][Full Text] [Related]
10. Further replication of the synergistic interaction between LPHN3 and the NTAD gene cluster on ADHD and its clinical course throughout adulthood.
Kappel DB; Schuch JB; Rovaris DL; da Silva BS; Cupertino RB; Winkler C; Teche SP; Vitola ES; Karam RG; Rohde LA; Bau CHD; Grevet EH; Mota NR
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):120-127. PubMed ID: 28624582
[TBL] [Abstract][Full Text] [Related]
11. LPHN3 and attention-deficit/hyperactivity disorder: a susceptibility and pharmacogenetic study.
Bruxel EM; Salatino-Oliveira A; Akutagava-Martins GC; Tovo-Rodrigues L; Genro JP; Zeni CP; Polanczyk GV; Chazan R; Schmitz M; Arcos-Burgos M; Rohde LA; Hutz MH
Genes Brain Behav; 2015 Jun; 14(5):419-27. PubMed ID: 25989180
[TBL] [Abstract][Full Text] [Related]
12. ADGRL3 (LPHN3) variants predict substance use disorder.
Arcos-Burgos M; Vélez JI; Martinez AF; Ribasés M; Ramos-Quiroga JA; Sánchez-Mora C; Richarte V; Roncero C; Cormand B; Fernández-Castillo N; Casas M; Lopera F; Pineda DA; Palacio JD; Acosta-López JE; Cervantes-Henriquez ML; Sánchez-Rojas MG; Puentes-Rozo PJ; Molina BSG; ; Boden MT; Wallis D; Lidbury B; Newman S; Easteal S; Swanson J; Patel H; Volkow N; Acosta MT; Castellanos FX; de Leon J; Mastronardi CA; Muenke M
Transl Psychiatry; 2019 Jan; 9(1):42. PubMed ID: 30696812
[TBL] [Abstract][Full Text] [Related]
13. Psychiatric Polygenic Risk Scores as Predictor for Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder in a Clinical Child and Adolescent Sample.
Jansen AG; Dieleman GC; Jansen PR; Verhulst FC; Posthuma D; Polderman TJC
Behav Genet; 2020 Jul; 50(4):203-212. PubMed ID: 31346826
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of boys with comorbid autism spectrum disorder and attention deficit/hyperactivity disorder.
Yamawaki K; Ishitsuka K; Suyama S; Suzumura S; Yamashita H; Kanba S
Pediatr Int; 2020 Feb; 62(2):151-157. PubMed ID: 31845457
[TBL] [Abstract][Full Text] [Related]
15. Language deficits in specific language impairment, attention deficit/hyperactivity disorder, and autism spectrum disorder: An analysis of polygenic risk.
Nudel R; Christiani CAJ; Ohland J; Uddin MJ; Hemager N; Ellersgaard DV; Spang KS; Burton BK; Greve AN; Gantriis DL; Bybjerg-Grauholm J; Jepsen JRM; Thorup AAE; Mors O; Nordentoft M; Werge T
Autism Res; 2020 Mar; 13(3):369-381. PubMed ID: 31577390
[TBL] [Abstract][Full Text] [Related]
16. LPHN3 and attention-deficit/hyperactivity disorder: interaction with maternal stress during pregnancy.
Choudhry Z; Sengupta SM; Grizenko N; Fortier ME; Thakur GA; Bellingham J; Joober R
J Child Psychol Psychiatry; 2012 Aug; 53(8):892-902. PubMed ID: 22486528
[TBL] [Abstract][Full Text] [Related]
17. Inattention and hyperactivity/impulsivity among children with attention-deficit/hyperactivity-disorder, autism spectrum disorder, and intellectual disability.
McClain MB; Hasty Mills AM; Murphy LE
Res Dev Disabil; 2017 Nov; 70():175-184. PubMed ID: 28957735
[TBL] [Abstract][Full Text] [Related]
18. Attention-deficit hyperactivity disorder shares copy number variant risk with schizophrenia and autism spectrum disorder.
Gudmundsson OO; Walters GB; Ingason A; Johansson S; Zayats T; Athanasiu L; Sonderby IE; Gustafsson O; Nawaz MS; Jonsson GF; Jonsson L; Knappskog PM; Ingvarsdottir E; Davidsdottir K; Djurovic S; Knudsen GPS; Askeland RB; Haraldsdottir GS; Baldursson G; Magnusson P; Sigurdsson E; Gudbjartsson DF; Stefansson H; Andreassen OA; Haavik J; Reichborn-Kjennerud T; Stefansson K
Transl Psychiatry; 2019 Oct; 9(1):258. PubMed ID: 31624239
[TBL] [Abstract][Full Text] [Related]
19. Risk of Psychiatric and Neurodevelopmental Disorders Among Siblings of Probands With Autism Spectrum Disorders.
Jokiranta-Olkoniemi E; Cheslack-Postava K; Sucksdorff D; Suominen A; Gyllenberg D; Chudal R; Leivonen S; Gissler M; Brown AS; Sourander A
JAMA Psychiatry; 2016 Jun; 73(6):622-9. PubMed ID: 27145529
[TBL] [Abstract][Full Text] [Related]
20. The Genetic Overlap of Attention-Deficit/Hyperactivity Disorder and Autistic-like Traits: an Investigation of Individual Symptom Scales and Cognitive markers.
Pinto R; Rijsdijk F; Ronald A; Asherson P; Kuntsi J
J Abnorm Child Psychol; 2016 Feb; 44(2):335-45. PubMed ID: 26021462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
